AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01152489 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Buzzy: sham device
Description: The identical device without batteries or a cold pack is held in place proximal to the site with a velcro strap or pressed by parent or nurse immediately prior to immunizations. The device remains in place throughout the procedure, moving locations to complete multiple shots.
Study NCT02022956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Study NCT01146041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: Rivastigmine 1.5 mg Capsules
Study NCT01146041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine
Description: Rivastigmine 1.5 mg Capsules
Study NCT03185104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Description: Silver diamine fluoride solution is applied to the dried and exposed coronal and root surfaces of all teeth by means of a disposable microbrush.
Study NCT03185104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Distilled Water
Description: Distilled water is applied to the dried and exposed coronal and root surfaces of all teeth by means of a disposable microbrush.
Study NCT03106012 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Description: rigid continuous flow diagnostic hysteroscopy (Tuttligen, Karl Storz, Germany). It has a 30o panoramic optic which is 4mm in diameter and the diagnostic continuous flow outer sheath is 6.5 mm in diameter.
Study NCT03106012 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Description: Veress needle was placed through the umbilicus and into the peritoneal cavity,After a pneumo-peritoneum has been achieved with a Veress needle, the primary trocar with sleeve (5mm in diameter) was placed at a similar angle in to the Veress needle
Study NCT04690257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trace Image and Coloring for Kids-Book (TICK-B)
Description: A collection of pictures designed as a book contains and given to children during the procedure and they take a picture as they favored.
Study NCT02278991 — intervention group
Intervention type: DEVICE
Intervention: Lutonix Drug Coated Balloon
Description: Subject will receive treatment with the Lutonix Drug Coated Balloon
Study NCT03655392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized educational program
Description: IG patients were submitted to three 30-minutes intervention of a individualized shortterm educational program delivered by a nurse, were given explanations about general aspects of the disease, prevention methods and about the importance and correct use of inhaled corticosteroids, with an educational video showing the use of the device
Study NCT03655392 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Induced sputum collection
Description: All participants performed induced sputum collection
Study NCT03655392 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Spirometry
Description: All participants performed spirometry test using a Koko spirometer. Pulmonary function was assessed by spirometry prebronchodilator, after withholding short-acting beta-agonists for ≥ 6 hours and long-acting beta-agonist for ≥ 24hours. Forced expiratory volume in one second (FEV1) % predicted was used as a proxy variable for overall lung function.
Study NCT03655392 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nitric oxide measure
Description: All participants performed nitric oxide measure in three Mylar bags and measure was performed in a NOA280 Sievers equipment. For collection the patients blew in the balloons through a sterile nozzle in the equipment collector without prejudice or damage to the patient.
Study NCT03655392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires ACT, ACQ, AQLQ, BDI
Description: All participants answered standardized questionnaires about asthma symptoms and depression: Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Quality Life Questionnaire (AQLQ), Beck Depression Inventory (BDI)
Study NCT03655392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptoms Diary
Description: All participants were instructed to note in the morning and evening before the use of routine inhaled corticosteroids, asthma symptoms (coughing, wheezing, shortness of breath, use of emergency inhaled corticosteroids) and three measures of peak expiratory flow (individual, provided to patients) and to return this completed diary at each study visit
Study NCT03655392 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Peak flow measure
Description: All participants registered three peak flow measures in the symptoms diary by morning and night before the use of routine inhaled corticosteroids. Peak flow was measured by the electronic peak flow meter (Mini-Wright).
Study NCT03655392 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Exhaled breath condensate air measurement
Description: Exhaled breath condensate was collect during 15 to 20 minutes in a Turbo DECCS equipment (Medivac SRL, Italy) in a sterile buccal of the own apparatus with the aid of a nasal clip with the participant breathing normally without any effort or damage.
Study NCT00082043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Study NCT00082043 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Study NCT00871572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: 4 capsules by mouth taken once daily for 12 weeks
Study NCT00871572 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules by mouth once daily for 12 weeks
Study NCT02330913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracorporeal esophagojejunostomy
Description: Under laparoscopic view, esophagojejunostomy was pereformed with 60mm linear stapler on right side of distal esophagus like as functional end-to-end fashion before esophageal and jejunal resection. Then, three procedures of esophageal resection, common entry hole closure and jejunal resection was performed with a single use of 60mm stapler. Also, jejunojejunostomy was also performed via already made staple entry hole.
Study NCT00709124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA)
Description: 60 minute NMES sessions will be applied to three muscle groups of the lower extremities (quadriceps, pretibial, and triceps surae). Sessions start at study entry, and will occur every day for the duration of subject's ICU stay.
Study NCT00709124 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: 60 minute NMES sessions will be applied to three muscle groups of the lower extremities (quadriceps, pretibial, and triceps surae). Sessions start at study entry, and will occur every day for the duration of subject's ICU stay. Sham groups will NOT have voltage applied.
Study NCT04137146 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sacral Nerve Stimulation
Description: Implantation of a sacral nerve neurostimulation system: A single electrode (Interstim® model 3889-28; Medtronic, Minneapolis, MN) was inserted bilaterally into the sacral foramen (S3), connected to an internal pulse generator (Medtronic Interstim~® II 3058)
Study NCT01236859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Neurontin®, Pfizer
Study NCT01236859 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin
Description: Neurontin®, Pfizer
Study NCT00719862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: Placebo
Study NCT03654274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/norethindrone acetate
Description: Capsule containing co-formulated tablet of E2 (1.0 mg) and NETA (0.5 mg) administered orally once daily
Study NCT04522934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: Patients received 24 sessions, in an 8-week period, of multimodal physiotherapy (therapeutic heat, manual therapy and exercises) along with four sessions of pain neuroscience education. The latter was focused on the influence of psychosocial factors in the experience of pain, differences between acute and chronic pain and central-peripheral awareness.
Study NCT00719862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.15% azelastine hydrochloride Nasal Spray
Description: 0.15% azelastine hydrochloride 822 mcg
Study NCT01287546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2875358
Description: Part A Dose escalation of LY2875358 administered intravenously (IV), Day 1 and 15 every 28 days for at least two cycles.
Study NCT01287546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2875358 + erlotinib
Description: Part A2 Dose escalation of LY2875358 administered IV, on Day 1 and 15 every 28 days for at least two cycles in combination with daily erlotinib dosing (150 mg) taken orally (PO).
Study NCT01287546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2875358 at Part A highest dose
Description: Part B (Dose Exploration): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles.
Study NCT01287546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2875358 at Part A highest dose + trametinib
Description: Part B (in combination with trametinib): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles, in combination with trametinib at 2 mg orally once daily
Study NCT03134924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Women's and Sexual Health [WASH]
Description: The WASH was a group-based, 45-minute group session on vaginal health and healthy vaginal practices led by two trained facilitators. The sessions covered topics related to vaginal practices and the potential harm of vaginal practices.
Study NCT03134924 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Enhanced Standard of Care
Description: The enhanced standard of care (SOC+) condition received a genital tract examination, collection of a vaginal swab with gram stain of vaginal secretions, diagnosis of BV, and medication as needed. At baseline participants received an individual education session on the risk of engaging in IVP and tips on discontinuing IVP.
Study NCT01250756 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 7-pneumococcal conjugate vaccine (7vPnC)
Description: 0.5 mL per dose, 4 doses
Study NCT01250756 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: diphtheria, tetanus, and acellular pertussis vaccine (DTaP)
Description: 0.5 mL per dose, 4 doses
Study NCT01250756 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP
Description: 0.5 mL per dose, 4 doses
Study NCT00209170 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beating the Blues
Description: Beating the Blues is a computerized cognitive behavioral therapy.
Study NCT00209170 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Beating the Blues
Description: Beating the Blues is a computerized cognitive behavioral therapy.
Study NCT00209170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant. It's a 10 mg pill taken once or twice daily for 6 months.
Study NCT00209170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A sugar pill taken as one to two tablets daily for 6 months.
Study NCT04480931 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Intervention Group
Description: Access to the mobile health application with exercise plans and education
Study NCT04480931 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Educational Brochure
Description: An evidence-based educational brochure with general information about the benefits of physical activity during pregnancy
Study NCT03579992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 60-min isometric MyCI training
Description: EMG-controlled in-lab training with arm restrained for 60 minutes per session
Study NCT03579992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 90-min isometric MyCI training
Description: EMG-controlled in-lab training with arm restrained for 90 minutes per session
Study NCT03579992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 90-min movement MyCI training
Description: EMG-controlled in-lab training without restraint for 90 minutes per session
Study NCT01481090 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture, Electro-Acupuncture
Description: Participants will receive 4 Electro-acupuncture stimulation applied to acupoints SP-6, Zi-Gong, CV-3 and CV-4acupuncture treatments during hormone treatment.
Study NCT02162121 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous lumbar plexus: stimulating catheter
Description: Perinervous stimulating catheter (Stimulong, Pajunk, Germany) will be insert in lumbar plexus through tuohy needle (18G, 100mm length). 15ml mepivacaine 1% are injected before the complete resolution of the spinal anesthesia.
Study NCT02162121 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia
Description: Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 15mg will be injected.
Study NCT02162121 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia
Description: Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 15mg will be injected.
Study NCT02162121 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic infusion
Description: Continuous infusion (Mini Rythmic Evolution, Micrel) of ropivacaine 0,2% at 3ml/h, bolus 3 ml, lockout time 15 min, 12 ml/h maximum dose through perinervous catheter until 3rd postoperative day
Study NCT02162121 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local anesthetic infusion
Description: Continuous infusion (Mini Rythmic Evolution, Micrel) of ropivacaine 0,2% at 3ml/h, bolus 3 ml, lockout time 15 min, 12 ml/h maximum dose through perinervous catheter until 3rd postoperative day
Study NCT02162121 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous analgesia
Description: Ketorolac 30mg 3 times a day
Study NCT02162121 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous analgesia
Description: Ketorolac 30mg 3 times a day
Study NCT02162121 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Opioids rescue analgesia
Description: Buprenorphine 0,2mg twice a day if VAS>4
Study NCT02162121 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Opioids rescue analgesia
Description: Buprenorphine 0,2mg twice a day if VAS>4
Study NCT02162121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine 1%
Study NCT02162121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine 1%
Study NCT02162121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine 0,5%
Study NCT02162121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0,5%
Study NCT02162121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0,2%
Study NCT02162121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0,2%
Study NCT02162121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac 30mg
Study NCT02162121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac 30mg
Study NCT02162121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine 0,2mg
Study NCT02162121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0,2mg
Study NCT02162121 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stimulong, Pajunk, Germany.
Study NCT02162121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulong, Pajunk, Germany.
Study NCT02162121 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous lumbar plexus: non-stimulating catheter
Study NCT05227482 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Personalized dosimetry approach
Description: The radionuclide activity to administer is calculated using personalized voxel-based dosimetry approach
Study NCT05227482 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard dosimetry approach
Description: The radionuclide activity to administer is calculated using standard (BSA or MIRD) dosimetry approach
Study NCT04430946 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standardized test meal
Description: A test meal of \~700 kcal consisting of protein and fat will be consumed within 10 minutes
Study NCT04430946 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standardized test meal
Description: A test meal of \~700 kcal consisting of protein and fat will be consumed within 10 minutes
Study NCT02022033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXA
Description: Abraxane: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)
Study NCT03539913 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic : Saccharomyces boulardii
Description: Treatment for 5 days
Study NCT03539913 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic : Bacillus clausii
Description: Treatment for 5 days
Study NCT01499901 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral cochlear Implantation in sequential
Description: bilateral cochlear Implantation in sequential
Study NCT01499901 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral cochlear Implantation in simultaneous
Description: bilateral cochlear Implantation in simultaneous
Study NCT03949140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser hair removal
Description: Those who consent to participate in the study will be treated with up to 8 sessions of laser hair removal utilizing a long-pulsed laser to the natal cleft at treatment intervals of 4-6 weeks.
Study NCT03398733 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: continuous positive airway pressure
Description: The CPAP treatment group received both baseline and CPAP treatment for 7 days preoperatively. The non-CPAP treatment group only received baseline treatment.
Study NCT03685487 — intervention group
Intervention type: PROCEDURE
Intervention: decolonization
Description: current practice : V1 : consultation to the service : nasal sample for all 5 days before surgery : order sent with decolonization procedure : nasal mupirocin, shower and mouthwash V2 : admission to the service : nasal sample for all and urine sample for decolonized patients V3 : nasal sample for all
Study NCT03685487 — intervention group
Intervention type: OTHER
Intervention: compliance questionnaire
Description: We asked if the patient has done the whole decolonization procedure
Study NCT02251678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elimune Capsules
Description: 2 capsules BID for 28 days
Study NCT04973410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Coronary Physiology
Description: Invasive coronary physiology measurements during diagnostic CAG with thermodilution method with the CoroFlow® (Coroventis, Uppsala, Sweden)
Study NCT04973410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 15O-H2O-PET scan
Description: Myocardial blood flow (MBF) measured with oxygen-15 (O-15) labelled water used as a tracer molecule with positron emission tomography (PET)
Study NCT00109772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Two 5 mg capsules taken one time per day
Study NCT00109772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo capsules taken one time per day
Study NCT03159806 — intervention group
Intervention type: DEVICE
Intervention: Microdialysis sampling
Description: Insertion of CE-marked intravenous microdialysis catheter, use of CE-marked microdialysis pump to collect intravenous microdialysis samples
Study NCT00370877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFVIIa
Description: The patients included in this arm of the study will recieve standard care for post-partum hemorrhage plus a slow intravenous injection (2ml/min) of rFVIIa (60µg/kg)
Study NCT00370877 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Patients will recieve standard care for post partum hemorrhage according to current recommendations.
Study NCT03748277 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompression
Description: Bilateral decompression
Study NCT03748277 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompression
Description: Bilateral decompression
Study NCT03748277 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PLIF
Description: Traditional open surgery